Acute myeloid leukemia (AML) is generally considered the most aggressive and deadly of the four main leukemia types, with a five-year survival rate of about 33%. But the full picture is more nuanced than a single ranking. Certain rare subtypes, genetic mutations, and circumstances like relapse or older age can make any leukemia far more dangerous. Here’s what actually drives the worst outcomes.
The Four Main Types, Ranked by Survival
Leukemia falls into four broad categories based on how fast it grows (acute vs. chronic) and which type of white blood cell it affects (myeloid vs. lymphoid). Their five-year survival rates differ dramatically:
- Chronic lymphocytic leukemia (CLL) has the best overall prognosis. Many people live with it for years without needing treatment.
- Chronic myeloid leukemia (CML) was once rapidly fatal but is now highly manageable with targeted oral medications, and most patients have near-normal life expectancy.
- Acute lymphoblastic leukemia (ALL) is curable in the majority of children, with five-year disease-free survival between 63% and 83%. In adults, those numbers drop to 28% to 39%.
- Acute myeloid leukemia (AML) sits at the bottom, with a five-year survival rate of 33.4% across all ages, based on the most recent SEER data covering 2016 to 2022.
AML earns its reputation as the worst common leukemia because it strikes fast, responds inconsistently to treatment, and disproportionately affects older adults whose bodies tolerate intensive chemotherapy poorly.
Why AML Is So Difficult to Treat
AML isn’t one disease. It’s a collection of subtypes driven by different genetic mutations, and some of those mutations make the cancer far more resistant to treatment. Mutations in the TP53 gene, for example, are linked to especially poor outcomes. The same is true for changes in genes called FLT3, RUNX1, ASXL1, and several others. When doctors analyze a patient’s leukemia cells and find these markers, it signals that standard chemotherapy is less likely to achieve a lasting remission.
One subtype, acute monocytic leukemia, is particularly aggressive because the cancerous cells tend to invade the brain and central nervous system. It crowds out healthy blood cells in the bone marrow, leading to severe anemia, infections from low white blood cell counts, and dangerous bleeding from low platelets. About 3 in 10 people with this subtype are alive five years after diagnosis, and stem cell transplant from a donor remains the only known cure.
Rare Subtypes With Even Worse Odds
If you look beyond the four main categories, some rare forms of leukemia carry a prognosis that makes even AML look favorable.
Plasma cell leukemia is one of the deadliest blood cancers in existence. It comes in two forms: primary, which arises on its own, and secondary, which develops when an existing cancer called multiple myeloma transforms into leukemia. A multicenter study found that overall median survival for plasma cell leukemia was just 6.7 months. The secondary form was far worse, with a median survival of only 1.6 months and a treatment response rate below 10%. Even the primary form, which responded better to therapy, had a median survival of about 16.6 months. Patients who received a stem cell transplant did significantly better, reaching a median survival around 33 months.
Therapy-related leukemia is another devastating category. This occurs when chemotherapy or radiation given for a previous cancer damages bone marrow cells and triggers a new leukemia years later. With conventional chemotherapy alone, median survival is under one year. Even with a stem cell transplant, only about 31% of patients survive three years, and the relapse rate at three years is around 40%.
When a “Mild” Leukemia Turns Aggressive
CLL is normally the most slow-moving leukemia, but between 2% and 10% of patients experience something called Richter’s transformation. The slow-growing cancer essentially converts into a fast, aggressive lymphoma. When this happens, survival drops sharply. Median survival after transformation has been reported as short as 9 months in patients who were already on certain CLL treatments. For those who hadn’t received prior therapy, outcomes were somewhat better at around 46 to 77 months, but the transformation still represents a dramatic shift in prognosis. From CLL diagnosis, patients who develop Richter’s transformation survive a median of just 1.7 years, compared to over 10 years for CLL patients who don’t transform.
Age Changes Everything
Perhaps the single biggest factor determining how deadly any leukemia becomes is the patient’s age at diagnosis. This is starkly visible in ALL. Over 95% of children achieve complete remission, and most are cured. Adults fare progressively worse: a 20-year-old has double the risk of treatment failure compared to a 10-year-old, and a 44-year-old has four times the risk, even when treated with similar protocols.
AML follows the same pattern. The majority of AML cases occur in people over 60, and older adults often cannot tolerate the intensive chemotherapy regimens that give younger patients their best chance. This is a major reason AML’s overall survival numbers are so low. The 2025 American Society of Hematology guidelines for older adults with AML now recommend combining lower-intensity chemotherapy with a targeted drug that blocks a protein leukemia cells rely on to survive. This combination reduces mortality over time by roughly 34% compared to low-intensity chemotherapy alone, a meaningful improvement for a group that previously had very few effective options.
What Happens When Treatment Fails
For any leukemia, relapse after initial treatment is one of the strongest predictors of a poor outcome. Relapsed or refractory ALL in adolescents and young adults historically carried a three-year survival rate of only 15% to 16% when treated with standard chemotherapy. Newer targeted therapies have improved this picture for some patients, but treatment failure remains the scenario where leukemia outcomes are at their worst regardless of the original subtype.
The same principle applies to AML. Patients whose leukemia doesn’t respond to the first round of induction chemotherapy, or who relapse within months of achieving remission, face significantly worse odds than those captured in overall survival statistics. Genetic testing at diagnosis increasingly helps doctors predict who is most likely to relapse, allowing treatment plans to be adjusted earlier.
What “Worst” Really Means
AML is the correct short answer when someone asks which leukemia is the worst. It kills more people annually than any other leukemia type and has the lowest overall survival rate of the four major categories. But the more precise answer depends on context. A 70-year-old diagnosed with AML carrying a TP53 mutation faces a very different reality than a 25-year-old with the same broad diagnosis but favorable genetics. Plasma cell leukemia and therapy-related leukemia have even grimmer statistics than AML, though they’re far less common. And even the “best” leukemia, CLL, can become one of the deadliest if it transforms. The subtype matters, the genetics matter, the patient’s age and fitness matter, and whether the cancer responds to initial treatment matters most of all.